BRPI1015043A2 - derivados de diazahomoadamantano e métodos de uso dos mesmos - Google Patents

derivados de diazahomoadamantano e métodos de uso dos mesmos

Info

Publication number
BRPI1015043A2
BRPI1015043A2 BRPI1015043A BRPI1015043A BRPI1015043A2 BR PI1015043 A2 BRPI1015043 A2 BR PI1015043A2 BR PI1015043 A BRPI1015043 A BR PI1015043A BR PI1015043 A BRPI1015043 A BR PI1015043A BR PI1015043 A2 BRPI1015043 A2 BR PI1015043A2
Authority
BR
Brazil
Prior art keywords
methods
diazahomoadamantane
derivatives
diazahomoadamantane derivatives
compounds
Prior art date
Application number
BRPI1015043A
Other languages
English (en)
Inventor
B Sippy Kevin
R Schrimpf Michael
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43354879&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1015043(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BRPI1015043A2 publication Critical patent/BRPI1015043A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

"derivados de diazahomoadamantano e métodos de uso dos mesmos" a invenção refere-se compostos que são derivados de diazahomoadamantano, composições compreendendo tais compostos, e métodos de usar tais compostos e composições.
BRPI1015043A 2009-06-19 2010-06-18 derivados de diazahomoadamantano e métodos de uso dos mesmos BRPI1015043A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21847909P 2009-06-19 2009-06-19
PCT/CN2010/000889 WO2010145208A1 (en) 2009-06-19 2010-06-18 Diazahomoadamantane derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
BRPI1015043A2 true BRPI1015043A2 (pt) 2019-07-09

Family

ID=43354879

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1015043A BRPI1015043A2 (pt) 2009-06-19 2010-06-18 derivados de diazahomoadamantano e métodos de uso dos mesmos

Country Status (15)

Country Link
US (1) US8846661B2 (pt)
EP (1) EP2443122B1 (pt)
JP (1) JP2012530084A (pt)
KR (1) KR20120044978A (pt)
CN (1) CN102459268A (pt)
AU (1) AU2010262643B2 (pt)
BR (1) BRPI1015043A2 (pt)
CA (1) CA2765466A1 (pt)
IL (2) IL216883A (pt)
MX (1) MX2011014019A (pt)
NZ (1) NZ597511A (pt)
PE (1) PE20121066A1 (pt)
RU (2) RU2549551C2 (pt)
SG (1) SG176921A1 (pt)
WO (1) WO2010145208A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2606052B1 (en) 2010-08-20 2016-06-01 Research Triangle Institute Nicotinic receptor compounds
CN103087001A (zh) * 2011-11-03 2013-05-08 南京大学 香草酸的1，3，4-噁二唑衍生物及其制法和用途
WO2014165090A1 (en) * 2013-03-13 2014-10-09 The Broad Institute, Inc. Compounds for the treatment of tuberculosis
RU2552649C1 (ru) * 2013-12-13 2015-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Душистые 5-бензил-1,3-диазаадамантан-6-оны
WO2015103005A1 (en) * 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
WO2016100184A1 (en) 2014-12-16 2016-06-23 Forum Pharmaceuticals, Inc. Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
KR20180044256A (ko) 2015-06-10 2018-05-02 엑소반트 사이언시즈 게엠베하 A7-니코틴성 아세틸콜린 수용체의 작용제로서의 아미노벤즈이소옥사졸 화합물
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US10874672B2 (en) 2015-12-10 2020-12-29 Ptc Therapeutics, Inc. Methods for treating Huntington's disease
CA3066224A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics Inc. Compounds for treating huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
WO2019005980A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
MX2020008375A (es) * 2018-02-08 2020-09-25 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Compuestos de heteroarilo, composiciones farmaceuticas de los mismos y su uso terapeutico.
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
EP3814357A1 (en) 2018-06-27 2021-05-05 PTC Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
IL123898A (en) * 1995-11-02 2001-08-08 Neurosearch As The history of compressed tropane, their preparation and the pharmaceutical preparations containing them
IL141050A0 (en) * 1998-08-18 2002-02-10 Ucb Sa Muscarinic agonists and antagonists
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
JP2007506723A (ja) * 2003-09-26 2007-03-22 アストラゼネカ・アクチエボラーグ 非アミド性ノナン
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
JP5566698B2 (ja) * 2007-03-23 2014-08-06 アッヴィ・インコーポレイテッド アザアダマンタンエステルおよびカーバメート誘導体ならびにそれらの使用方法
CA2679874A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof
US8168791B2 (en) * 2007-03-23 2012-05-01 Abbott Laboratories Aminomethyl azaadamantane derivatives and methods of use thereof
SG178557A1 (en) * 2009-09-14 2012-03-29 Suven Life Sciences Ltd L -dihydro-2-oxoquinoline compounds a 5-ht4 receptor ligands

Also Published As

Publication number Publication date
JP2012530084A (ja) 2012-11-29
EP2443122A1 (en) 2012-04-25
MX2011014019A (es) 2012-02-22
CA2765466A1 (en) 2010-12-23
IL216883A0 (en) 2012-02-29
PE20121066A1 (es) 2012-09-13
EP2443122A4 (en) 2012-12-19
EP2443122B1 (en) 2014-03-05
NZ597511A (en) 2014-01-31
IL216883A (en) 2015-02-26
KR20120044978A (ko) 2012-05-08
US8846661B2 (en) 2014-09-30
SG176921A1 (en) 2012-01-30
AU2010262643B2 (en) 2015-02-19
CN102459268A (zh) 2012-05-16
US20100324027A1 (en) 2010-12-23
RU2015110025A (ru) 2015-08-20
RU2549551C2 (ru) 2015-04-27
RU2012101784A (ru) 2013-07-27
AU2010262643A1 (en) 2012-02-02
IL236830A0 (en) 2015-03-31
WO2010145208A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
ECSP10010722A (es) Compuestos orgánicos
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
BR112012014082A2 (pt) composições e métodos que compreendem variantes de protease
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
EA200802008A1 (ru) Фармацевтические композиции
ECSP10010095A (es) 2'-fluoro-2'-desoxitetrahidrouridinas como inhibidores de citidina desaminasa
CO6190510A2 (es) Inhibidores del virus de la hepatitis c
NO20090596L (no) Antivirale fosfinatforbindelser
BRPI0914682B8 (pt) compostos de heteroarila e composições compreendendo os referidos compostos
NO20091845L (no) Macrocykliske peptider som hepatitt C virus-inhibitorer
CY1115919T1 (el) Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων
BRPI0813341A2 (pt) " uso de compostos, composições curáveis, e, uso de composições curáveis ".
CR11157A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
HK1133642A1 (en) Azaadamantane ester and carbamate derivatives and methods of use thereof
CR11251A (es) Depsipeptidos ciclicos y usos de los mismos
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
PA8792401A1 (es) Fenilendiaminas
EA201000069A1 (ru) Новые гербициды
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
UY30801A1 (es) Compuestos calciliticos
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
BR112013016431A2 (pt) novos derivados de amidas de biarila
TR201109686T2 (tr) Olmesartan'ın Farmasötik Bileşimleri.
ATE552832T1 (de) Antidepressivum-propharmaka

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2532 DE 16-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B25B Requested transfer of rights rejected

Owner name: ABBOTT LABORATORIES (US)

Free format text: INDEFERIDO(S) O(S) PEDIDO(S) DE TRANSFERENCIA(S) CONTIDO(S) NA PETICAO 020130078191 DE 25/09/2013 EM VIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2548 DE 05/11/2019.

B350 Update of information on the portal [chapter 15.35 patent gazette]